Trahanas John M, Witer Lucas J, Alghanem Fares, Bryner Benjamin S, Iyengar Amit, Hirschl Jacob R, Hoenerhoff Mark J, Potkay Joseph A, Bartlett Robert H, Rojas-Pena Alvaro, Owens Gabe E, Bocks Martin L
From the *Extracorporeal Life Support Laboratory, Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan; †Department of Surgery, Columbia University Medical Center, New York, New York; ‡In Vivo Animal Core, Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, Michigan; §Advanced Platform Technology Center, VA Ann Arbor Health Care System, Ann Arbor, Michigan; ¶Department of Surgery, Section of Transplant Surgery, and ‖Department of Pediatric Cardiology, University of Michigan Health Systems, Ann Arbor, Michigan.
ASAIO J. 2016 Jul-Aug;62(4):470-6. doi: 10.1097/MAT.0000000000000382.
Although total body perfusion with extracorporeal life support (ECLS) can be maintained for weeks, individual organ perfusion beyond 12 hours has yet to be achieved clinically. Normothermic ex situ heart perfusion (ESHP) offers the potential for prolonged cardiac preservation. We developed an ESHP system to study the effect of perfusate variables on organ preservation, with the ultimate goal of extending organ perfusion for ≥24 hours. Forty porcine hearts were perfused for a target of 12 hours. Hearts that maintained electromechanical activity and had a <3× increase in vascular resistance were considered successful preservations. Perfusion variables, metabolic byproducts, and histopathology were monitored and sampled to identify factors associated with preservation failure. Twenty-two of 40 hearts were successfully preserved at 12 hours. Successful 12 hour experiments demonstrated lower potassium (4.3 ± 0.8 vs. 5.0 ± 1.2 mmol/L; p = 0.018) and lactate (3.5 ± 2.8 vs. 4.5 ± 2.9 mmol/L; p = 0.139) levels, and histopathology revealed less tissue damage (p = 0.003) and less weight gain (p = 0.072). Results of these early experiments suggest prolonged ESHP is feasible, and that elevated lactate and potassium levels are associated with organ failure. Further studies are necessary to identify the ideal perfusate for normothermic ESHP.
尽管体外生命支持(ECLS)可维持全身灌注数周,但临床上尚未实现单个器官超过12小时的灌注。常温离体心脏灌注(ESHP)为延长心脏保存时间提供了可能。我们开发了一种ESHP系统,以研究灌注液变量对器官保存的影响,最终目标是将器官灌注时间延长至≥24小时。对40个猪心脏进行了12小时的灌注。维持机电活动且血管阻力增加<3倍的心脏被认为是成功保存。监测并采集灌注变量、代谢副产物和组织病理学样本,以确定与保存失败相关的因素。40个心脏中有22个在12小时时成功保存。成功的12小时实验显示钾(4.3±0.8 vs. 5.0±1.2 mmol/L;p = 0.018)和乳酸(3.5±2.8 vs. 4.5±2.9 mmol/L;p = 0.139)水平较低,组织病理学显示组织损伤较轻(p = 0.003)且重量增加较少(p = 0.072)。这些早期实验结果表明延长ESHP是可行的,且乳酸和钾水平升高与器官衰竭有关。有必要进行进一步研究以确定常温ESHP的理想灌注液。